Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1163-1174

  Wuelfing, W Peter ^a   Kwong, Elizabeth ^a,b   Higgins, John ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Kwong Eureka Solutions   (Canada)

Author keywords

dose proportionality; drug absorption; formulation; maximum absorbable dose; modeling; rat; solubility

Indexed keywords

MACROGOL 400; METHYLCELLULOSE;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; RATS; SOLUBILITY;

EID: 84860784465     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200452r     Document Type: Article

References (30)

1. Palucki, M.; Higgins, J.; Kwong, E.; Templeton, A. C. Strategies at the Interface of Drug Discovery and Development: Early Optimization of the Solid State Phase and Preclinical Toxicology Formulation for Potential Drug Candidates J. Med. Chem. 2010, 53, 5897-5905
2. Thakker, D. R. Strategic Use of Preclinical Pharmacokinetics Studies and In Vitro Models in optimizing ADME Properties of Lead Compounds. In Biotechnology: Pharmaceutical Aspects, Vol. IV: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds.; Springer: New York, 2006; pp 1-24.
3. Gan, L.-S.; Lee, F. W.; Nelamangala, N.; Li, P.; Labutti, J.; Yin, W.; Xia, C.; Yang, H.; Uttamsingh, V.; Lu, C.; Pulsakar, S.; Daniels, J. S.; Huang, R.; Qian, M.; Wu, J.-T.; Cardoza, K.; Balani, S. K.; Miwa, G. T. Case History-Use of ADME Studies for Optimization of Drug Candidates. In Biotechnology: Pharmaceutical Aspects, Vol. IV: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds.; Springer: New York, 2006; pp 81-98.
4. Hageman, M. J. Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization. In Biotechnology: Pharmaceutical Aspects, Vol. IV: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds.; Springer: New York, 2006; pp 99-130.
5. Caldwell, G. W. Compound optimization in early- and late-phase drug discovery; acceptable pharmacokinetic properties utilizing combined physicocohemical, in vitro and in vivo screens Curr. Opin. Drug Discovery Dev. 2000, 3, 30-41
6. Chen, X.-Q.; Antman, M. D.; Christoph, G.; Gudmundson, O. S. Discovery Pharmaceutics - Challenges and Opportunities. AAPS J. 2006, 8, Article 46, E402-E407.
7. Hilgers, A. R.; Smith, D. P.; Biermacher, J. J.; Day, J. S.; Jensen, J. L.; Sims, S. M.; Adams, W. J.; Fiis, J. M.; Palandra, J.; Hosley, J. D.; Shobe, E. M.; Burton, P. S. Pharm. Res. 2003, 20, 1149-1155
8. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the Golden Triangle to optimize clearance and oral absorption Bio. Med. Chem. Lett. 2009, 19, 5560-5564
9. Neervannan, S. Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2006, 2, 715-731
10. Pouton, C. W.; Porter, C. J. Formulation of Lipid Based Delivery Systems for Oral Administration: Materials, Methods, and Strategy Adv. Drug Delivery Rev. 2008, 60, 673-691
11. Merisko-Liversidge, E. M.; Liversidge, G. G. Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds Toxicol. Pathol. 2008, 36, 43-48
12. Friesen, D.; Shankar, R.; Crew, M.; Smithey, D.; Curatolo, W.; Nightingale, J. A. S. Hydroxypropyl methylcellulose acetate succinate based spray-dried dispersions: An overview Mol. Pharmaceutics 2008, 5, 1003-1009
13. Lipinski, C. Drug-like properties and the causes of poor solubility and poor permeability J. Pharm. Toxicol. 2000, 44, 235-249
14. Curatolo, W. Physical Chemical Properties of Oral Drug Candidates in the Discovery and Exploratory Development Settings Pharm. Sci. Technol. Today 1998, 1, 387-393
15. Sun, D.; Yu, L. X.; Hussain, M. A.; Wall, D. A.; Smith, R. L.; Amidon, G. L. In-vitro testing of drug absorption for drug "developability" assessment: Forming an interface between in-vitro preclinical data and clinical outcomes Curr. Opin. Drug Discovery Dev. 2004, 7, 75-85
16. Gu, C.-H.; Li, H.; Levons, J.; Lentz, K.; Ganghi, R. B.; Raghavan, K.; Smith, R. L. Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties Pharm. Res. 2007, 24, 1118-1130
17. Johnson, K. C.; Swindell, A. C. Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption Pharm. Res. 1996, 13, 1795-1798
18. Oh, D. M.; Curl, R.; Amidon, G. Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model Pharm. Res. 1993, 10, 264-270
19. Rohrs, B. Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure. In Biotechnology: Pharmaceutical Aspects, Vol. IV: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds.; Springer: New York, 2006; pp 151-166.
20. GastroPlus from Simulationsplus Inc. Information at www.simulations-plus. com/ (accessed June 12, 2011).
21. Intellipharm Software, LLC. Informationat www.intellipharm.com (accessed June 12, 2011).
22. Gao, Y.; Carr, R.; Spence, J. K.; Wang, W. W.; Turner, T. M.; Lipari, J. M.; Miller, J. M. A pH-Dilution Method for Estimation of Biorelevant Drug Solubility Along the Gastrointestinal Tract: Application to Physiologically Based Pharmacokinetic Modeling Mol. Pharmaceutics 2010, 5, 1516-1526
23. Nomier, A. A.; Morrison, R.; Prelusky, D.; Korfmacher, W.; Broske, V.; Hesk, D.; McNamara, P.; Mei., H. Estimation of the Extent of the Oral Absorption in Animals from Oral and Intravenous Pharmacokinetic Data in Drug Discovery J. Pharm. Sci. 2009, 98, 4027-4037
24. Sugano, K. Fraction of a dose absoprbed estimation for structurally diverse low solubility compounds Int. J. Pharm. 2011, 405, 79-80
25. McConnell, E. L.; Basit, A. W.; Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid, lymphoid tissue, and implications for in-vivo experiments J. Pharm. Pharmacol. 2008, 60, 63-70
26. Hochman, J.; Mei, Q.; Yamazaki, M.; Tang, C.; Prueksaritanont, T.; Bock, M.; Ha, S.; Lin, J. Role of Mechanistic Transport Studies in Lead Optimization. In Biotechnology: Pharmaceutical Aspects, Vol. IV: Optimizing the "Drug-Like"Properties of Leads in Drug Discovery; Borchardt, R. T.; Hageman, M. J.; Stevens, J. L.; Kerns, E. H.; Thakker, D. R., Eds.; Springer: New York, 2006; pp 25-48.
27. Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Oral Dosage Forms J. Pharm. Sci. 1998, 1, 11-22
28. Mudra, D.; Borchardt, R. T. Absorption Barriers in the Rat Intestinal Mucosa. 3: Effects of Polyethoxylated Solubilizing Agents on Drug Permeation and Metabolism J. Pharm. Sci. 2010, 99, 1016-1027
29. Cuine, J. F.; McEvoy, C. L.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Benameur, H.; Porter, C. J. H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 2008, 97, 995-1012
30. Fernandez, S.; Jannin, V.; Rodier, J.-D.; Ritter, N.; Mahler, B.; Carriere, F. Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain triglycerides and PEG esters Biochem. Biophys. Acta 2007, 1771, 633-640